Detailed dose evidence documented for Pramlintide in its monograph — reference only, not dosing recommendations.
Reference only — not a dosing recommendation.
Approved regimen
Approved labeled regimen
Product-, indication-, and jurisdiction-specific — see the monograph
The entries summarize the cited US FDA Symlin label for its approved adjunctive uses with mealtime insulin.
T1D: Initial 15 mcg SC before each major meal; titrate in 15-mcg increments every 3–7 days to maintenance 60 mcg if tolerated.
T2D: Initial 60 mcg SC before each major meal; titrate in 60-mcg increments to maintenance 120 mcg.
Concurrent mealtime insulin dose must be reduced by 50% at initiation.
Studied in trials
Studied regimens (not recommendations)
Studied in trials — not a recommended dose
Higher doses (up to 180 mcg) studied but not labeled.
No sustained-release or long-acting formulation has been approved.
Not established
What is not established
No data for use without concurrent mealtime insulin.
Safety and efficacy in pediatric patients younger than 18 years not established.
Available human pregnancy data are insufficient to determine a drug-associated risk; the current FDA label does not use the former pregnancy letter-category system.